Skip to content
IRWDIronwood Pharmaceuticals Inc

Earnings

When Ironwood Pharmaceuticals Inc reports, what it reported each quarter, and how the stock took the results.

60 quarters. Mar 31, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 24, before the open

Wed, Feb 24, 2027in 99 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 16 – Mar 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$47.71M
Revenue, change from a year earlier: Q3 2026 +9.0%, Q2 2026 +32.6%, Q1 2026 +158.9%, Q4 2025 −47.3%
Net income
-$2.28M
Net income, change from a year earlier: Q3 2026 +49.3%, Q2 2026 +117.3%, Q1 2026 n/m, Q4 2025 n/m
EPS
-$0.01
EPS, change from a year earlier: Q3 2026 +56.5%, Q2 2026 +121.4%, Q1 2026 n/m, Q4 2025 n/m

Quarter by quarter

Q3 2026$133.04M+9.0% vs Q3 2025

Latest results

  1. Q3 2026Nov 5, 2026, before the openThe release+6.5%by the close of Nov 5
    Revenue
    $133.04M
    +9.0%
    Net income
    $59.84M
    +49.3%
    EPS
    $0.36
    +56.5%
  2. Q2 2026Aug 6, 2026, before the openThe release+3.1%by the close of Aug 6
    Revenue
    $113.04M
    +32.6%
    Net income
    $51.29M
    +117.3%
    EPS
    $0.31
    +121.4%
  3. Q1 2026May 7, 2026, before the openThe release14.1%by the close of May 7
    Revenue
    $106.51M
    +158.9%
    Net income
    $40.77M
    N/M
    EPS
    $0.24
    N/M
  4. Q4 2025Feb 25, 2026, before the openThe release11.1%by the close of Feb 25
    Revenue
    $47.71M
    −47.3%
    Net income
    -$2.28M
    N/M
    EPS
    -$0.01
    N/M

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · pre-marketNov 5, 202636 d10-Q$133.04M+9.0%$0.36+6.5%
Q2 2026Jun 30, 2026Aug 6, 2026 · pre-marketAug 6, 202637 d10-Q$113.04M+32.6%$0.31+3.1%
Q1 2026Mar 31, 2026May 7, 2026 · pre-marketMay 7, 202637 d10-Q$106.51M+158.9%$0.2414.1%
FY 2025
Q4 2025Dec 31, 2025Feb 25, 2026 · pre-marketFeb 26, 202657 d10-K$47.71M−47.3%-$0.0111.1%
Q3 2025Sep 30, 2025Nov 10, 2025 · pre-marketNov 10, 202541 d10-Q$122.06M+33.3%$0.23+32.7%
Q2 2025Jun 30, 2025Aug 7, 2025 · pre-marketAug 11, 202542 d10-Q$85.24M−9.7%$0.14+8.5%
Q1 2025Mar 31, 2025May 7, 2025 · pre-marketMay 12, 202542 d10-Q$41.14M−45.1%-$0.2314.6%
FY 2024
Q4 2024Dec 31, 2024Feb 27, 2025 · pre-marketMar 31, 202590 d10-K$90.55M−23.0%$0.015.3%
Q3 2024Sep 30, 2024Nov 7, 2024 · pre-marketNov 7, 202438 d10-Q$91.59M−19.5%$0.027.7%
Q2 2024Jun 30, 2024Aug 8, 2024 · pre-marketAug 8, 202439 d10-Q$94.40M−12.1%-$0.01—
Q1 2024Mar 31, 2024May 9, 2024 · pre-marketMay 9, 202439 d10-Q$74.88M−28.0%-$0.0317.6%
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026123319
10-QAug 6, 2026091987
10-QMay 7, 2026057110
10-KFeb 26, 2026020489
10-QNov 10, 2025108795
10-QAug 11, 2025011050
10-QMay 12, 2025007406
10-KMar 31, 2025004072
10-QNov 7, 2024014909
10-QAug 8, 2024011590

Provenance

ProvenanceData status and checks

Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR